Navitor Pharmaceuticals, Inc.
http://www.navitorpharma.com/index.html
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Navitor Pharmaceuticals, Inc.
Deal Watch: Novartis Partners With TScan To Develop T-Cell Receptor-Targeted Therapies
Novartis/TScan and Gilead/Kite/oNKo-innate partnerships seek to advance cancer cell therapy. J&J, Bayer among the latest pharmas to unveil partnerships to fight the novel coronavirus.
Appointments: Senior Hires At IGM, Cell Medica, Mologen, Navitor, Tenaya, Oncobiologics, Provention Bio And Centrexion
New CEOs have been appointed at Cell Medica, Mologen, Navitor Pharmaceuticals, Tenaya Therapeutics and Oncobiologics, while a new CMO has been recruited to IGM Biosciences, a vice president of clinical development at Provention Bio and a CFO at Centrexion Therapeutics.
resTORbio's Age-Related RTI Program Picks Up Further Funding
Clinical studies by resTORbio into age-related immunosenescence attracts investors keen to advance a potential new class of immunotherapy agents.
Where Will CNS Drug Development Go In 2018?
The world's expanding, aging population means diseases of the central nervous system, like Alzheimer's and Parkinson's, are potential blockbuster areas for innovative pharma and biotech companies that are able to navigate clinical studies and get to market. Scrip looks at five emerging trends that are likely to affect the CNS drug development landscape in 2018.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Drug Discovery Tools
- ADMET